NUR 2407 ATI Pharm Made Easy - Hematalogic (Summer 202) complete solution Help - Rasmussen College, Ocala.

ATI - Pharm Made Easy: Hematologic A healthcare professional is administering epoetin alfa (Epogen) subcutaneously to a patient who has renal failure. The healthcare professional should take which of the following actions? A) Shake the vial before using. B) Insert the needle into the vial once. C) Dilute the drug first with normal saline. D) Save the used vial for the next dose. ANS: B. A) Shaking the vial can damage the glycoprotein that comprises the drug, making it ineffective. B) Instructions for administering the drug include inserting the needle into the vial only once. Health care professionals should also examine the solution and discard it if it is cloudy or discolored. C) Instructions for administering the drug preclude mixing it with other drugs or solutions. Health care professionals should also examine the solution and discard it if it is cloudy or discolored. D) Instructions for administering the drug include using the vial only once and then discarding it. Health care professionals should also examine the solution and discard it if it is cloudy or discolored. A healthcare professional is caring for a patient who has a known sensitivity to Escherichia coliderived proteins. This sensitivity is a contraindication for which of the following drugs? A) Epoetin alfa (Erythropoietin). B) Oprelvekin (Neumega). C) Filgrastim (Neupogen). D) Alteplase (Activase). ANS: C. A) Patients who have uncontrolled hypertension or iron-deficiency anemia should not receive epoetin alfa, an erythropoietic factor. B) Patients who are undergoing myeloablative chemotherapy should not receive oprelvekin, a thrombopoietic growth factor. C) Patients who are sensitive to Escherichia coli-derived proteins or have acute respiratory distress syndrome should not receive filgrastim, a leukopoietic growth factor. D) Patients who have active internal bleeding or pericarditis should not receive alteplase, a thrombolytic. A healthcare professional is caring for a patient who has mild hemophila A and is about to begin taking desmopressin (DDAVP) to prevent bleeding. The healthcare professional should monitor for which of the following adverse reactions? A) Weight loss. B) Edema. C) Polyuria. D) Tachycardia ANS: B. A) Desmopressin, an antidiuretic hormone, can cause hyponatremia and weight gain. Health care professionals should monitor serum sodium levels and daily weight for patients receiving the drug therapy. B) Desmopressin, an antidiuretic hormone, can cause fluid retention and edema. Health care professionals should monitor fluid intake and output for patients receiving the drug therapy. C) Desmopressin, an antidiuretic hormone, can reduce urine output. It is unlikely to cause polyuria. D) Desmopressin, an antidiuretic hormone, can cause a slight increase in blood pressure. It is unlikely to cause tachycardia. A healthcare professional is caring for a patient who is about ot begin taking folic acid to treat megaloblastic anemia. The healthcare professional should monitor which of the following laboratory values? A) Amylase level. B) Reticulocyte count. C) Folic acid D) C-reactive protein. E) Creatinine clearance ANS: B. A) Folic acid, also called folate, is unlikely to alter amylase levels. Amylase is an enzyme that helps digest carbohydrates. Levels rise with pancreatic inflammation or injury. B) A reticulocyte count measures the amount of immature RBCs. Folic acid, also called folate, is essential for erythropoiesis. Patients who have a foli